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aspase activation is a key event in apoptosis execu-
tion. In stress-induced apoptosis, the mitochondrial
pathway of caspase activation is believed to be of
central importance. In this pathway, cytochrome c released
from mitochondria facilitates the formation of an Apaf-1
apoptosome that recruits and activates caspase-9. Recent
data indicate that in some cells caspase-9 may not be the
initiator caspase in stress-mediated apoptosis because
 
caspase-2 is required upstream of mitochondria for the
release of cytochrome c and other apoptogenic factors. To
determine how caspase-2 is activated, we have studied the
C
 
formation of a complex that mediates caspase-2 activation.
Using gel ﬁltration analysis of cell lysates, we show that
caspase-2 is spontaneously recruited to a large protein
complex independent of cytochrome c and Apaf-1 and that
recruitment of caspase-2 to this complex is sufﬁcient to
mediate its activation. Using substrate-binding assays, we
also provide the ﬁrst evidence that caspase-2 activation
may occur without processing of the precursor molecule.
Our data are consistent with a model where caspase-2
activation occurs by oligomerization, independent of the
Apaf-1 apoptosome.
 
Introduction
 
The execution of apoptosis is performed by a family of cysteine
proteases known as caspases (for review see Nicholson,
1999). Caspases are present as zymogens in most animal
cells and are activated in response to apoptotic signals. The
apoptotic signals first lead to the activation of so called “initiator
caspases,” such as caspase-8 and caspase-9. These caspases
contain specific protein–protein interaction domains in their
 
NH
 
2
 
 termini that allow them to be recruited to death-signaling
complexes promoting their activation by an autocatalytic
mechanism (for review see Kumar, 1999). Once the initiator
caspases are activated, they process and activate downstream
 
effector caspases, such as caspase-3, -6 and -7, which are
responsible for the cleavage of several proteins in dying cells
(Nicholson, 1999).
In mammals, there are two main caspase activation pathways:
the death receptor pathway and the mitochondrial pathway
(Kumar, 1999; Nicholson, 1999). In the first pathway, TNF
receptor family members recruit Fas-associated protein with
death domain (FADD),* an adaptor molecule that in turn
recruits caspase-8 to the death-inducing signaling complex
(DISC). Recruitment of caspase-8 to DISC results in its
activation. The mitochondrial pathway of caspase activation
is regulated by the Bcl-2 family of proteins and involves cyto-
chrome c and Apaf-1–mediated activation of caspase-9.
During stress signaling, cytochrome c released from mito-
chondria binds Apaf-1, resulting in a conformational
change that facilitates oligomerization of Apaf-1 into an
apoptosome and subsequent caspase recruitment domain
(CARD)–mediated recruitment and activation of caspase-9
(Acehan et al., 2002). Interestingly, initiator caspase DRONC
activation in 
 
Drosophila
 
 cells does not seem to require release
of cytochrome c from mitochondria (Dorstyn et al., 2002).
Although caspase-9 is generally believed to be the initiator
caspase in stress-induced apoptosis, recent studies suggest that
caspase-2 can act upstream of mitochondria (Lassus et al.,
2002; Robertson et al., 2002). The new findings indicate that
caspase-2 is the initiator caspase in stress-induced apoptosis,
whereas apoptosome mediated caspase-9, and subsequently
caspase-3, activation may mainly serve as an amplification loop
(Kumar and Vaux, 2002). Caspase-2, the first discovered
apoptotic mammalian caspase, has been implicated in a variety
of cell death pathways, and consistent with an initiator role it is
activated rapidly in response to diverse death stimuli (Kumar et
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al., 1994, 1997; Wang et al., 1994; Kumar, 1995; Harvey et
al., 1997). Since caspase-2
 
 
 
/
 
 
 
 mice have only a subtle pheno-
type, it is likely that in the absence of this caspase other similar
caspases functionally replace caspase-2 (Bergeron et al., 1998).
Although the process of caspase-9 activation via Apaf-1
apoptosome has been well studied, the mechanism of cas-
pase-2 activation is not known. Caspase-2 can homodimer-
ize and autoprocess in yeast and mammalian cells, but an
Apaf-1-like adaptor has not been found for caspase-2 and it
is not known whether an apoptosome-like complex is re-
quired for its activation (Butt et al., 1998). Because caspase-2
can be processed into subunits by caspase-3 and this pro-
cessing is blocked in caspase-3–depleted extracts and cells
derived from Apaf-1 and caspase-9–deficient mice, caspase-2
has often been suggested to be a downstream caspase
(Harvey et al., 1996; Slee et al., 1999; O’Reilly et al., 2002).
However, since caspase-9 activation can occur without pro-
cessing (Stennicke et al., 1999) it is possible that initial cas-
pase-2 activation may also occur without its cleavage and
that caspase-3–mediated caspase-2 processing is simply a
downstream amplification mechanism. In this paper, we re-
port that caspase-2 is recruited to a large protein complex in-
dependent of cytochrome c and Apaf-1 and that this recruit-
ment is sufficient for caspase-2 activation. We also provide
data to suggest that initial caspase-2 activation is likely to oc-
cur without any processing of the precursor.
 
Results and discussion
 
Recruitment of caspase-2 to a large protein complex
 
We have shown previously that caspase-2 overexpression in
mammalian cell lines results in the formation of elaborate
filamentous structures that are dependent on the prodomain
of caspase-2 (Colussi et al., 1998a,b). To further dissect the
ability of caspase-2 to form large complexes, we subjected
whole cell lysates from HeLa cells to size exclusion chroma-
tography. Size exclusion chromatography has been used suc-
cessfully by several groups to show the formation of the
Apaf-1 apoptosome (Cain et al., 1999, 2000; Zou et al.,
1999). Upon the addition of cytochrome c and dATP to cell
lysates containing monomeric Apaf-1 and caspase-9, these
proteins were found to interact via their CARDs to form a
complex 
 
 
 
700 kD in size (Cain et al., 1999, 2000; Zou et
al., 1999). Our results showed that in untreated HeLa ly-
sates, caspase-2 eluted mainly as monomeric zymogen (Fig.
1 A). Interestingly, incubation of the cell lysates at 37
 
 
 
C for
1 h without the addition of cytochrome c and dATP re-
sulted in a dramatic change in the elution behavior of
caspase-2 (Fig. 1 A). Approximately 50% of the caspase-2
was now associated with fractions corresponding to a molec-
ular mass of 
 
 
 
670 kD (Fig. 1).
The lack of requirement for cytochrome c and dATP ad-
dition for the formation of this complex suggests that either
there is sufficient cytochrome c and dATP in the cell extracts
or that these components are not required for the generation
of the caspase-2 complex. In all experiments described in
this paper, we found that it was unnecessary to add cy-
tochrome c and dATP for the formation of caspase-2 or
Apaf-1 complex. Similar results were obtained with extracts
prepared from the murine neuroblastoma cell line N18 (un-
published data) and human embryonic kidney 293T cells
(see below), suggesting that the recruitment of caspase-2 to a
putative high molecular weight complex is not cell specific.
In experiments where the lysates supplemented with cyto-
Figure 1. Caspase-2 is recruited to a large protein complex. HeLa cell lysates were subjected to size exclusion chromatography (A and B). 
Aliquots from the fractions were analyzed by immunoblotting using the monoclonal antibody 11B4 that recognizes the p19 subunit and 
full-length caspase-2. Cells were lysed in buffer A and incubated at 4 or 37 C for 60 min before loading onto the column. In B, lysates were 
incubated at 4 or 37 C for 2 h with 2  g cytochrome c and 2 mM dATP. The elution positions of the markers on the Superdex 200 column are 
indicated. The positions of the SDS-PAGE prestained Mr standards are indicated on the right of the blots. The smaller caspase-2 immunoreactive 
band is prodomain p19 processing intermediate that is often detected in cell lysates, probably due to some processing of procaspase-2 
during cell harvesting and lysis. 
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chrome c and dATP were incubated at 37
 
 
 
C for 
 
 
 
2 h, pro-
cessing of procaspase-2, likely to be mediated by active
caspase-3, was clearly evident in both low and high 
 
M
 
r
 
 frac-
tions (Fig. 1 B).
 
Caspase-2 complex is sensitive to ionic concentration 
and requires the prodomain
 
A time course demonstrated that the formation of caspase-2
complex is rapid and complete. Within 30 min of incubation
at 37
 
 
 
C, 
 
 
 
30% of the monomeric caspase-2 was recruited to
the large complex, whereas a 2-h incubation was sufficient
for 
 
 
 
75% of caspase-2 to shift to the high molecular mass
complex in fractions 4–6 (unpublished data). Previous stud-
ies have shown that physiological levels of KCl or NaCl pre-
vent the formation of the apoptosome in vitro, suggesting
that this may be a mechanism to ensure that inadvertent
caspase activation does not occur in healthy cells (Cain et al.,
2001). In similar experiments, we prepared HeLa cell lysates
in salt-free buffer and supplemented them with either 150
mM KCl or 150 mM NaCl. The addition of the 150 mM
salt to HeLa lysates strongly inhibited the caspase-2 complex
formation (Fig. 2 A). Thus, as is the case for the apoptosome,
inadvertent caspase-2 complex formation may be prevented
by normal cytoplasmic salt concentrations.
To test if caspase-2 CARD was necessary for its recruit-
ment to the large complex, we fractionated extracts prepared
from cells transfected with a caspase-2 construct lacking the
prodomain and found that upon incubation at 37
 
 
 
C this
form of caspase-2 was not recruited to the large complex
(Fig. 2 B). This result suggests that CARD is necessary for
procaspase-2 recruitment into the complex.
 
The elution profile of caspase-2 complex is similar to 
that of the Apaf-1 apoptosome
 
The size of the caspase-2 complex corresponds to that of the
Apaf-1 apoptosome. To test if the apoptosome and the
caspase-2 complex coelute in the same fractions, we probed
the fractions obtained from the size exclusion column with
Apaf-1, caspase-9, and caspase-3 antibodies. As shown in
Fig. 3, in untreated extracts all three proteins were present in
the fractions corresponding to their relative monomeric mo-
lecular mass as has been shown previously (Cain et al., 1999,
2000; Zou et al., 1999). However, after incubation of ex-
tracts at 37
 
 
 
C for 1 h all of the Apaf-1 and 
 
 
 
50% of the en-
dogenous caspase-9 was recruited to a high 
 
M
 
r
 
 complex in
fractions that also contained caspase-2. A small fraction of
procaspase-3 was also present in the same high molecular
mass fractions. These data suggest that caspase-2 is either a
part of the Apaf-1 and caspase-9 apoptosome or a complex
of similar size to the apoptosome.
 
Caspase-2 complex formation occurs independent of 
cytochrome c and Apaf-1
 
Although caspase-2 was detected in the same fractions as
Apaf-1/cytochrome c apoptosome, we were unable to detect
caspase-2 in Apaf-1 immunoprecipitations from fractions
Figure 2. Salt and prodomain dependence of caspase-2 complex. (A) HeLa cell lysates in 20 mM Hepes, pH 7.5, were supplemented with 
either 150 mM KCl or NaCl as indicated before incubation at 37 C for 60 min. Only selected fractions 2–8 and 19–25 were analyzed by 
immunoblotting. (B) Lysates from control HEK 293T cells or those transfected with a GFP-tagged prodomain-less caspase-2 expression 
construct were incubated at 37 C for 1 h and subjected to size exclusion chromatography. Fractions were immunoblotted with the caspase-2 
antibody (top) or a GFP antibody (bottom). Note that prodomain-less caspase-2–GFP fusion protein ( 60 kD) appears as monomer and dimer 
but was not detected in the high Mr fractions. Full-length caspase-2–GFP (Cys mutant) protein expressed in HEK 293T cells was largely insoluble 
and therefore could not be used in fractionation experiments. 
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2–6, which suggested that caspase-2 is unlikely to directly
interact with Apaf-1 (unpublished data). To test if caspase-2
complex formation requires cytochrome c, we used HeLa ly-
sates depleted of cytochrome c or prepared cell extracts by
digitonin treatment to prevent lysis of mitochondria. As
shown in Fig. 4 B, the lack of cytochrome c had no apparent
effect on caspase-2 complex formation. To analyze if Apaf-1
was necessary for caspase-2 complex, we used a myeloid cell
line derived from Apaf-1 knock-out mice. Extracts prepared
from Apaf-1–deficient cells were analyzed by gel filtration,
and as shown in Fig. 4 B caspase-2 recruitment to the high
molecular weight fractions was unaffected in these cells.
These results indicate that caspase-2 is not recruited to the
high molecular weight complex via an interaction with
Apaf-1 and that caspase-2 complex forms independently of
the Apaf-1/cytochrome c apoptosome. One possibility is
that caspase-2 is recruited to this high molecular weight
complex by interacting with an adaptor molecule function-
ally similar to Apaf-1. One candidate adaptor molecule for
caspase-2 is RAIDD, which is known to interact with
caspase-2 via a CARD (Duan and Dixit, 1997; Shearwin-
Whyatt et al., 2000). However, we were unable to detect any
RAIDD in the high molecular weight fractions (unpub-
lished data), ruling out the involvement of RAIDD in
caspase-2 complex formation.
 
Recruitment to the large complex results in 
activation of caspase-2
 
Although caspase-2 is structurally similar to the initiator
caspases, previous studies have shown that procaspase-2 is a
substrate for caspase-3–mediated activation and depletion of
caspase-3, or its upstream regulators caspase-9 and Apaf-1,
blocks processing of procaspase-2 (Harvey et al., 1996; Slee
et al., 1999; O’Reilly et al., 2002). How then can we recon-
cile the role of caspase-2 upstream of mitochondria? One
possibility is that the initial activation of caspase-2 occurs
without any significant processing of procaspase-2, and
caspase-2 zymogen cleavage by caspase-3 is a downstream
event that acts as an amplification mechanism to fully and
irreversibly activate all cellular caspase-2. Some support for
this hypothesis comes from the observation that most of the
caspase-2 in the large complex is in its zymogen form; how-
ever, longer incubation (
 
 
 
2 h) of cell extracts at 37
 
 
 
C with
cytochrome c and dATP resulted in mostly processed
caspase-2 (Fig. 1 B), suggesting that this required activation
of downstream caspases, such as caspase-3, which was fully
activated by 2 h (unpublished data).
Since there are no specific substrates for caspase-2, and the
most widely used caspase-2 substrate VDVAD is also readily
cleaved by several other caspases including caspase-3 and
caspase-7 (unpublished data), we tested if we can distinguish
active caspase-2 from inactive form by its ability to directly
bind a substrate/inhibitor. As suggested for caspase-9 zy-
mogen activation (Stennicke et al., 1999; Renatus et al.,
2001), if caspase-2 is initially activated by a conformational
change, the active form might be detected by its ability to
bind biotin–VAD. To this end, fractions from HeLa lysates
separated by size exclusion chromatography were incubated
with biotin–VAD-fmk, precipitated with streptavidin-cou-
pled Sepharose, and the precipitate was subjected to immu-
noblotting using anti–caspase-2 antibody. As shown in Fig.
5 A, fractions collected from control lysates did not show
any biotin–VAD-fmk binding. However, fractions 4–7 from
HeLa lysate incubated at 37
 
 
 
C contained caspase-2 with the
Figure 3. The caspase-2 complex is similar to the apoptosome. Treated HeLa lysates were subjected to size exclusion chromatography. 
Aliquots of the fractions were immunoblotted using antibodies to caspase-2 (Casp2), Apaf-1, caspase-9 (Casp9), and caspase-3 (Casp3). 
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ability to bind biotin–VAD-fmk (Fig. 5 B). This result sug-
gests the recruitment of caspase-2 to the high molecular
weight complex enables the activation of caspase-2 as mea-
sured by substrate binding. Interestingly, the fractions
containing monomeric caspase-2 did not show any biotin–
VAD-fmk binding. We repeated this experiment with col-
umn fractions collected from Apaf-1
 
 
 
/
 
 
 
 lysates. Again, the
high molecular weight fractions contained caspase-2 protein
capable of binding biotin–VAD-fmk (Fig. 5 C). These re-
sults show that although the monomeric procaspase-2 is
largely inactive, caspase-2 in the high molecular weight com-
plex is catalytically active. Furthermore, whereas the caspase-2
complex resembles the Apaf-1/caspase-9 apoptosome, our
data suggest that the complex forms independently of Apaf-1
and that Apaf-1 is not required for caspase-2 activation.
Although it is possible to demonstrate the formation of
the Apaf-1/caspase-9 apoptosome in cell lysates, it has been
difficult to isolate this complex from intact cells in response
to a cell death stimulus. In some studies, Apaf-1 was shown
to migrate to fractions of 
 
 
 
700 kD in size in extracts pre-
pared from cells treated with cytotoxic drugs (Zou et al.,
1999; Almond et al., 2001). However, to our knowledge no
one has demonstrated the recruitment of caspases to the pu-
tative Apaf-1 complex in dying cells. This may indicate the
transient nature of the apoptosome in vivo and the fact that
only a small fraction of cellular caspase-9 is recruited to the
apoptosome at a given time, making it technically difficult
 
to experimentally observe it. Similarly, we were unable to see
any caspase-2 in high 
 
M
 
r
 
 fractions of cell extracts prepared
from etoposide-treated HeLa cells, although these cells did
show recruitment of a part of the monomeric Apaf-1 pool to
the large complex (unpublished data). Since the putative
adaptor required for caspase-2 activation is currently un-
known, it was not possible to see whether an Apaf-1–like
complex specific for caspase-2 activation was being formed
in vivo. We are currently in the process of identifying the
components of the caspase-2 complex using proteomics-
based approaches. This will help us delineate fully the mo-
lecular mechanism of caspase-2 activation.
 
Materials and methods
 
Cell culture and preparation of lysates
 
HeLa cells were maintained in DME supplemented with 10% FBS and 1
mM glutamine. Apaf-1 wild-type and Apaf-1
 
 
 
/
 
 
 
 cells (retrovirally immortal-
ized murine fetal liver cells) were maintained in DME with 10% FBS, 1 mM
glutamine and 1/4,000 recombinant murine IL-3 (a gift from A.F. Lopez,
Hanson Institute). To prepare lysates, cells were washed twice with PBS and
resuspended in buffer A (20 mM Hepes-KOH, 10 mM KCl, 1 mM MgCl
 
2
 
, 1
mM EDTA, 1 mM EGTA, 1 mM DTT, pH 7.5) supplemented with protease
inhibitors (Complete™; Roche). Resuspended cells were subjected to three
rounds of freeze thawing using liquid nitrogen and ice water. Cellular de-
bris was removed by centrifugation at 9,000 
 
g
 
, 20 min at 4
 
 
 
C, followed by
100,000 
 
g
 
, 30 min at 4
 
 
 
C. Cleared lysates were stored at 
 
 
 
20
 
 
 
C until re-
quired. Where indicated, depletion of cytochrome c from cell extracts was
performed as described (Dorstyn et al., 2002). To maintain mitochondria
integrity in some experiments, cells were lysed by homogenization in a
Figure 4. Formation of caspase-2 complex is independent of cytochrome c and Apaf-1. In A and B, HeLa cell lysates were prepared by 
digitonin lysis or freeze/thawing. Immunoblotting in A, lane 1, demonstrated that digitonin lysates do not have any detectable cytochrome c 
(Cyt c). Cytochrome c from the freeze/thaw lysates was removed by immunodepletion. As shown in A, lane 3, immunodepleted cell extracts 
do not have any detectable cytochrome c. In B, digitonin lysates (DIG) and cytochrome c–depleted lysates (CDFT) were incubated at 37 C for 
60 min, subjected to size exclusion chromatography, and analyzed by immunoblotting using a caspase-2 antibody. (C) Lysates from Apaf-1
 /  
cells were incubated at 4 or 37 C for 60 min and subjected to size exclusion chromatography. Fractions were precipitated with 10% TCA/0.07% 
 -mercaptoethanol/acetone at  20 C. Protein pellets were washed with cold 0.07%  -mercaptoethanol/acetone and resuspended in 1  SDS 
protein loading buffer. The entire sample was resolved by SDS-PAGE and analyzed by immunoblotting with the caspase-2 antibody. 
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buffer containing 0.1 mg/ml digitonin (Bourgeron et al., 1992). HEK 293T
cells were grown in RPMI1640 with 10% FBS. Cell were transfected with a
catalytically inactive caspase-2–GFP expression construct lacking the pro-
domain as described (Colussi et al., 1998a). Cell lysates from untransfected
and transfected cells were prepared by freeze thawing as above.
 
Chromatographic methods
 
Treated lysates were fractionated using FPLC protein purification system
on a Superdex 200 column (Amersham Biosciences) at 4
 
 
 
C. The column
was equilibrated with buffer A, and lysates (5 mg) were applied and eluted
from the column with buffer A at a flow rate of 0.4 ml/min and 400-
 
 
 
l frac-
tions were collected. The column was calibrated with Bio-Rad Laborato-
ries gel filtration standards containing bovine thyroglobulin (670 kD),
horse gamma globulin (158 kD), chicken ovalbumin (44 kD), horse myo-
globin (17 kD), and vitamin B-12 (1.35 kD).
 
Immunoblotting
 
25 
 
 
 
l of each fraction from gel filtration column were resolved on 8–15%
SDS–polyacrylamide gels and transferred to polyvinylidine difluoride
membrane (Hybond-P; Amersham Biosciences). Membranes were blocked
in 5% blocking solution (Amersham Biosciences) before probing with anti-
bodies to caspase-2 (11B4) (O’Reilly et al., 2002), Apaf-1 (12F11) (O’Reilly
et al., 2002), caspase-9 (B40) (BD PharMingen), cytochrome c (BD Phar-
Mingen), GFP (Roche), and caspase-3 (BD PharMingen). Antibody binding
was detected using goat anti–rat IgG (Pierce Chemical Co.), sheep anti–
mouse IgG (Silenus), or sheep anti–rabbit IgG (Silenus), all conjugated to
alkaline phosphatase, and ECF (Amersham Biosciences) using the Typhoon
9410 and ImageQuant software (Amersham Biosciences).
 
Detection of active caspase-2
 
Whole cell lysates (50 
 
 
 
g) or 100–200 
 
 
 
l of Superdex 200 column frac-
tions were incubated with 2 
 
 
 
M biotin–VAD-fmk (Enzyme Systems) for 60
 
min at RT. Reaction volumes were made up to 1 ml in buffer A and the bi-
otin–VAD-fmk–reacting proteins were precipitated by incubation with
streptavidin-coupled Sepharose overnight at 4
 
 
 
C on a rotator. After wash-
ing with buffer A plus
 
 
 
0.1% Tween 20, Sepharose bound proteins were re-
solved by SDS-PAGE and immunoblotting with the caspase-2 antibody.
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